<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of uncomplicated non-falciparum malaria</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of uncomplicated non-falciparum malaria</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of uncomplicated non-falciparum malaria</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="10%"></colgroup><colgroup span="2" width="35%"></colgroup><colgroup width="10%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Drug</td> <td class="subtitle1">Adult dosing</td> <td class="subtitle1">Pediatric dosing</td> <td class="subtitle1">Pregnancy*</td> </tr> <tr class="divider_bottom"> <td> <p><strong><em>P. vivax</em></strong></p> <p><strong><em>P. ovale</em></strong></p> (chloroquine-sensitive)</td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <p><strong>Hydroxy-chloroquine<sup>¶</sup></strong></p> <p>PLUS</p> <strong>Primaquine<sup>Δ</sup></strong></td> <td> <p><strong>Chloroquine</strong> 600 mg base (=1000 mg salt) orally immediately, followed by 300 mg base (=500 mg salt) orally at 6, 24, and 48 hours. Total dose: 1500 mg base (=2500 mg salt)</p> <p><strong>Hydroxychloroquine</strong> 620 mg base (=800 mg salt) orally immediately, followed by 310 mg base (=400 mg salt) orally at 6, 24, and 48 hours. Total dose: 1550 mg base (=2000 mg salt)</p> <strong>Primaquine<sup>Δ</sup><sup>◊</sup></strong> 30 mg base orally once daily for 14 days</td> <td> <p><strong>Chloroquine</strong> 10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg</p> <p><strong>Hydroxychloroquine</strong> 10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg</p> <strong>Primaquine<sup>Δ</sup><sup>◊</sup></strong> 30 mg base orally once daily for 14 days</td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <strong>Hydroxy-chloroquine<sup>¶</sup></strong></td> </tr> <tr> <td class="divider_bottom" rowspan="2"> <p><strong>Chloroquine-resistant <em>P. vivax</em><sup>§</sup></strong></p> (Papua New Guinea and Indonesia)</td> <td> <p><strong>A. Mefloquine</strong></p> <p>OR</p> <p><strong>Atovaquone-proguanil (Malarone)</strong></p> <p>PLUS</p> <strong>Primaquine<sup>Δ</sup></strong></td> <td> <p><strong>A. Mefloquine</strong> 648 mg base (=750 mg salt) orally as initial dose, followed by 456 mg base (=500 mg salt) orally given 6 to 12 hours after initial dose (total dose = 1250 mg salt)</p> <p><strong>Atovaquone-proguanil (Malarone)</strong> Adult tab = 250 mg atovaquone / 100 mg proguanil. </p> <p>4 adult tabs orally once daily for 3 days</p> <strong>Primaquine</strong> (as above)</td> <td> <p><strong>A. Mefloquine</strong> 13.7 mg base/kg (=15 mg salt/kg) orally as initial dose, followed by 9.1 mg base/kg (=10 mg salt//kg) orally given 6 to 12 hours after initial dose (total dose = 25 mg salt/kg)</p> <p><strong>Atovaquone-proguanil (Malarone)</strong> Peds tab=62.5 mg atovaquone/ 25 mg proguanil. </p> <p>All doses administered orally once daily for 3 days: 5 to 8 kg: 2 peds tabs; 9 to 10 kg: 3 peds tabs; 11 to 20 kg: 1 adult tab; 21 to 30 kg: 2 adult tabs; 31 to 40 kg: 3 adult tabs; &gt;40kg: 4 adult tabs </p> <strong>Primaquine</strong> (as above)</td> <td><strong>A. Mefloquine</strong> (only)</td> </tr> <tr class="divider_bottom"> <td> <p><strong>B. Quinine</strong></p> <p>PLUS one of the following:</p> <p><strong>Doxycycline</strong></p> <p><strong>Tetracycline</strong></p> <p>PLUS</p> <strong>Primaquine<sup>Δ</sup></strong></td> <td> <p><strong>B. Quinine<sup>¥</sup></strong> 542 mg base (=650 mg salt) orally three times daily x 3 to 7 days</p> <p><strong>Doxycycline</strong> 100 mg orally twice daily x 7 days</p> <p><strong>Tetracycline</strong> 250 mg orally four times daily x 7 days</p> <strong>Primaquine</strong> (as above)</td> <td> <p><strong>B. Quinine<sup>¥</sup></strong> 8.3 mg base/kg (=10 mg salt/kg) orally three times daily x 3 to 7 days</p> <p><strong>Doxycycline<sup>‡</sup></strong> 2.2 mg/kg orally twice daily x 7 days</p> <p><strong>Tetracycline<sup>‡</sup></strong> 25 mg/kg/day orally divided four times daily x 7 days</p> <strong>Primaquine</strong> (as above)</td> <td><strong>B. Quinine</strong> (only)</td> </tr> <tr> <td> <p><strong><em>P. malariae</em></strong></p> <strong><em>P. knowlesii</em></strong></td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <strong>Hydroxy-chloroquine<sup>¶</sup></strong></td> <td> <p><strong>Chloroquine</strong> (as above)</p> <strong>Hydroxychloroquine</strong> (as above)</td> <td> <p><strong>Chloroquine</strong> (as above)</p> <strong>Hydroxychloroquine</strong> (as above)</td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <strong>Hydroxy-chloroquine<sup>¶</sup></strong></td> </tr> </tbody></table></div><div class="graphic_footnotes">* Dosing as for adults. Primaquine, doxycycline, and tetracycle are contraindicated in pregnancy.<br/>¶ Hydroxychloroquine is a second line alternative to chloroquine.<br/>Δ Primaquine is used to prevent <em>P. vivax</em> and <em>P. ovale </em>relapse by eradicating hypnozoite forms that may remain dormant in the liver. Because primaquine can cause hemolytic anemia in persons with G6PD deficiency, screening for G6PD deficiency is required prior to starting treatment with primaquine. Primaquine is contraindicated in pregnancy given uncertain neonatal G6PD status.<br/><font class="lozenge">◊</font> To prevent relapse of <em>P. vivax</em>, primaquine should be dosed 30 mg/day for 14 days. To prevent relapse of <em>P. ovale</em>, primaquine should be dosed 15 mg base/day for 14 days. Primaquine therapy should begin on the same day of treatment with chloroquine.<br/>§ For treatment of uncomplicated malaria due to chloroquine-resistant <em>P. vivax,</em> there are two options (A or B) that are equally recommended. Individuals with <em>P. vivax </em>infection acquired outside of Papua New Guinea or Indonesia should be started on chloroquine; if the patient does not respond, the treatment should be changed to a chloroquine-resistant <em>P. vivax </em>regimen.<br/>¥ For infections acquired in Southeast Asia, quinine treatment should continue for seven days. For infections acquired in Africa and South America, quinine treatment should continue for three days. In the United States, quinine is encapsulated in a 324 mg dose; therefore, for adult dosing, two capsules are sufficient. For pediatric dosing, if non-capsule forms are not available, atovaquone-proguanil or mefloquine may be used. Dosing for atovaquone-proguanil is outlined separately (see "Treatment of malaria").<br/>‡ Doxycycline and tetracycline are not indicated for use in children &lt;8 years. For children &lt;8 years with chloroquine-resistant <em>P. vivax</em>, quinine (given alone for seven days) or mefloquine may be used. If these options are not available or not tolerated and if treatment benefits outweigh the risks, doxycycline or tetracycline may be given to children &lt;8 years.</div><div id="graphicVersion">Graphic 67642 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
